Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.59 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931212 | 0.85 | ALDH1A1 (0.54) | SCN8ASCN10A | |
| SCHEMBL21327408 | 0.85 | SCN8A (0.60) | SCN8ASCN10AHTTTTR | |
| Benzoic Acid SCHEMBL29179815 | 0.84 | SCN8A (0.51) | SCN8ASCN10AHTTTTR | |
| SCHEMBL15561844 | 0.83 | SCN8A (0.67) | SCN8ASCN10A | |
| SCHEMBL21327604 | 0.82 | HTT (0.50) | SCN8ASCN10AHTT | |
| SCHEMBL21327413 | 0.81 | HTT (0.51) | SCN8ASCN10AHTTTTR | |
| SCHEMBL20639166 | 0.80 | SCN8A (0.43) | SCN8ASCN10AHTTTTR | |
| SCHEMBL21327584 | 0.80 | HTT (0.71) | HTTTTR | |
| 2-Picolinic Acid SCHEMBL29179803 | 0.79 | SCN8A (0.46) | SCN8ASCN10A | |
| SCHEMBL15561837 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| EP-3651752-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-12 | — | — | US | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| US-9421196-B2 | Amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-9312497-B2 | Heterocyclic compound, organic light-emitting diode including the heterocyclic compound, and flat display device including the organic light-emitting diode | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-04-12 | — | — | US | disclosed |
| EP-2951155-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150328196-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-19 | — | — | US | disclosed |
| US-9108903-B2 | Amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2014120820-A9 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20140221435-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014120820-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603351-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SCN8A 19/4885SCN10A 3/4885HTT 1309/4885 |
| US-20150328196-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN1A, SCN5A, TRPV1 | SCN8A 16/4885SCN10A 7/4885HTT 1663/4885 |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | SCN8A 19/4885SCN10A 3/4885HTT 1309/4885 |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SCN8A 19/4885SCN10A 3/4885HTT 1309/4885 |
| US-20140221435-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN1A, SCN5A, TRPV1 | SCN8A 16/4885SCN10A 7/4885HTT 1663/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | SCN8A 19/4885SCN10A 3/4885HTT 1309/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SCN8A 19/4885SCN10A 3/4885HTT 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.